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The Molecular Basis for Phosphodependent Substrate
Targeting and Regulation of Plks
by the Polo-Box Domain
tein kinases involved in cell-cycle control function, in
part, by generating phosphoserine/threonine-containing
sequence motifs in their substrates that are subse-
quently recognized by phosphoserine/threonine binding
proteins. These include the WW and proline isomerase
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domain of Pin1 that regulates mitotic progression, 14-Department of Biology
3-3 proteins that control the G2/M transition in responseMassachusetts Institute of Technology
to DNA damage, and the WD40 repeat of Cdc4p thatCambridge, Massachusetts 02139
regulates S phase entry (Yaffe and Elia, 2001).2 National Institute for Medical Research
In several instances, a phosphopeptide binding do-Division of Protein Structure
main and a kinase domain are combined within a singleLondon, NW7 1AA
molecule, best exemplified by the SH2 domain-con-United Kingdom
taining Src kinases and the Rad53p/Chk2-family of FHA3 Division of Signal Transduction
domain-containing kinases. In these proteins, the phos-Department of Cell Biology
phopeptide binding domain targets the kinase to pre-Beth Israel Deaconess Hospital
phosphorylated (primed) sites, mediates processiveHarvard Medical School
phosphorylation at multiple sites within a single sub-Boston, Massachusetts 02215
strate, or facilitates kinase activation. Polo-like kinases
are distinguished by the presence of a conserved Ser/
Thr kinase domain and a noncatalytic C-terminal regionSummary
composed of two homologous 70–80 residue seg-
ments termed Polo boxes (Sonnhammer et al., 1998).Polo-like kinases (Plks) perform crucial functions in
Using a proteomic screen for phosphoserine/threoninecell-cycle progression and multiple stages of mitosis.
binding domains, we recently identified the entire C-ter-Plks are characterized by a C-terminal noncatalytic
minal region of human Plk1 as a phosphoserine/threo-region containing two tandem Polo boxes, termed the
nine binding domain, the Polo-box domain (PBD), whichPolo-box domain (PBD), which has recently been im-
appears to target Plk1 to mitotic structures and sub-plicated in phosphodependent substrate targeting. We
strates (Elia et al., 2003).show that the PBDs of human, Xenopus, and yeast
Humans, mice, and frogs contain three Plk homologsPlks all recognize similar phosphoserine/threonine-
denoted Plk1, Plk2/Snk, and Plk3/Fnk/Prk, while bud-containing motifs. The 1.9 A˚ X-ray structure of a human
ding yeast, fission yeast, and flies contain only a singlePlk1 PBD-phosphopeptide complex shows that the
Plk family member denoted Cdc5p, Plo1, and Polo, re-Polo boxes each comprise 6 structures that associ- spectively. In addition, humans and mice contain a ser-ate to form a 12-stranded  sandwich domain. The
ine/threonine kinase, Sak, which is an extremely diver-phosphopeptide binds along a conserved, positively
gent member of the Plk family, containing only a singlecharged cleft located at the edge of the Polo-box inter-
Polo box and lacking a canonical PBD. The most exten-face. Mutations that specifically disrupt phospho-
sively studied Polo-like kinases, Plk1 and Cdc5p, have
dependent interactions abolish cell-cycle-dependent
been implicated in numerous mitotic processes includ-
localization and provide compelling phenotypic evi-
ing activation of Cdc25C and Cdc2-cyclin B at the G2-M
dence that PBD-phospholigand binding is necessary transition, centrosome maturation and spindle assem-
for proper mitotic progression. In addition, phospho- bly, cohesin release/cleavage during sister chromatid
peptide binding to the PBD stimulates kinase activity in separation, APC activation during mitotic exit and septin
full-length Plk1, suggesting a conformational switching regulation during cytokinesis (Descombes and Nigg,
mechanism for Plk regulation and a dual functionality 1998; Nigg, 1998; Glover et al., 1998). In contrast, human
for the PBD. Plk2 and Plk3 appear to serve different functions. Plk2
shows peak expression and activity in early G1 (Ma
Introduction et al., 2003) while Plk3 is activated by several stress
response pathways, including DNA damage and spindle
Cyclin-dependent kinases (Cdks) have long been con- disruption (Bahassi et al., 2002; Xie et al., 2001, 2002). In
sidered the master regulators of the cell cycle, but an fact, Plk3 plays some roles that may directly antagonize
increasing number of diverse protein kinases are now Plk1 function. For example, DNA damage directly inhib-
emerging as critical components of cell-cycle progres- its Plk1 (Smits et al., 2000) but activates Plk3 in an ATM-
sion. Among these are members of the Polo-like kinase dependent manner (Xie et al., 2001). Consistent with
family (Plks) that play key roles during all stages of mito- these results, Plk1 overexpression causes oncogenic
sis and in the cell cycle checkpoint response to geno- transformation in NIH 3T3 cells (Smith et al., 1997) while
toxic stress (Nigg, 1998; Glover et al., 1998). Many pro- overexpression of Plk3 induces apoptosis (Conn et al.,
2000). At present, the mechanisms underlying these
functional differences are unknown.*Correspondence: stephen.smerdon@nimr.mrc.ac.uk (S.J.S.), myaffe@
In spite of the variable roles played by different Plk-mit.edu (M.B.Y.)
4 These authors contributed equally to this work. family members, all require the activity of the Polo-box
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domain for correct subcellular localization (Lee et al., The striking selection observed for Ser in the pThr-1
1998; Ma et al., 2003; May et al., 2002; Reynolds and position in all PBDs was examined in detail for the human
Ohkura, 2003). Whether the PBDs in other Plks also Plk1 PBD, which binds to its optimal motif, Pro-Met-
bind phosphoserine/threonine-containing motifs is not Gln-Ser-pThr-Pro-Leu (Supplemental Table S1 available
known. Here, we show that the PBDs from human Plk1, at Cell website), with a Kd of 280 nM (Figure 1A). A
2, and 3, as well as the Plk1 orthologs Plx1 from Xenopus variety of small side-chain amino acids were therefore
and budding yeast Cdc5p all show conserved selection substituted in the pThr-1 position, and peptide binding
for the core sequence S-[pS/pT]-P/X in oriented peptide to the Plk1 PBD measured using isothermal titration
library screens. The crystal structure of the human Plk1 calorimetry (ITC) (Figure 1A). Surprisingly, conservative
PBD in complex with its optimal phosphopeptide motif replacement of Ser with Gly, Ala, Thr, or Cys, completely
reveals a mode of binding in which the bulk of the pep- abrogated Plk1 PBD-phosphopeptide binding. We had
tide contacts involve a specific lattice of water-mediated previously observed that replacement of Ser at the
hydrogen bonds. Site-directed mutagenesis based on pThr-1 position with Val, the amino acid showing the
the structural identification of critical phosphothreonine lowest selection in this position, was sufficient to elimi-
binding residues shows that phosphodependent sub- nate peptide binding (Elia et al., 2003). Nevertheless,
strate recognition by the PBD is necessary for Plk tar- the finding that replacement of Ser with a variety of
geting to substrates both in vitro and in vivo, and for chemically similar amino acids also completely dis-
proper mitotic progression. Furthermore, binding of the rupted the interaction between the PBD and free phos-
optimal Plk1 phosphopeptide to the PBD in full-length phopeptides in solution was unexpected.
Plk1 enhances the in vitro activity of the kinase domain, To extend this analysis, each amino acid in the eight
leading to a model for Plk regulation in which intramolec- positions flanking the pThr within the optimal Plk1 PBD
ular inhibition of the kinase by the PBD is relieved by binding motif was substituted with each of the remaining
PBD-ligand binding. We conclude that phosphoserine/
nineteen naturally occurring amino acids using a solid
threonine-dependent binding is a general feature of PBD
phase array of immobilized phosphopeptides (Figure 1Bactivity across the Plk family and critically important in
and Supplemental Data available at Cell website). ThisPolo-like kinase targeting and regulation.
conclusively demonstrated that only Ser was tolerated
in the pThr-1 position. Selectivities at other positionsResults
were generally consistent with the results of oriented
peptide library screening. Cys and Gly, however, wereA Common Consensus Motif Is Recognized
selected at the pThr1 position at least as strongly asby All Plk Polo-Box Domains
Pro in the immobilized phosphopeptide assay. TheseOptimal phosphopeptide binding motifs for the PBDs
subtle differences most likely reflect the fact that thefrom all members of the human Plk family, Xenopus Plx1
peptide filter assay examines individual point mutationsand Saccharomyces cerevisiae Cdc5p were determined
in the context of a single amino acid sequence, whileby oriented peptide library screening (Yaffe and Cantley,
oriented peptide library screening samples an entire en-2000) (Supplemental Data available at http://www.cell.
semble of sequence motifs simultaneously. Regardless,com/cgi/content/full/115/1/83/DC1). Since we initially
Pro probably represents the most “physiological” aminoisolated the Plk1 PBD in a search for domains that recog-
acid in the pThr1 position, since the phosphorylationnize a pThr-Pro-containing motif, primary screens were
event necessary for PBD binding is likely to be catalyzedperformed using peptide libraries containing a fixed
primarily by Pro-directed kinases such as Cdks andpThr-Pro core flanked on both sides by four degenerate
MAP kinases.positions. Each of the five PBD’s examined selected for
distinct but largely overlapping motifs and all showed
unequivocal selection for Ser in the pThr-1 position with Overall Structure of the Plk1 PBD
selectivity ratios (i.e., the mol% of Ser in the PBD bound The boundaries of the minimal PBD within the C-terminal
peptides at the pThr-1 position divided by the mol% of regions of both Plk1 and Cdc5p were determined using
Ser in the starting library mixture at the pThr-1 position) limited proteolysis. Digestion of the entire C-terminal
ranging from 3.0 to 7.5 (Supplemental Tables S1 and S2 region of Plk1 (residues 326–603) using V8 protease and
available at above website). Motif similarity occurs even trypsin indicated that only the last 45 residues of the
though these PBDs vary considerably in amino acid linker between the kinase domain and the first Polo box
sequence and the respective human Plks perform diver- were structured as part of the PBD (Figure 2A and data
gent cellular functions. not shown). Similar results were obtained using the
Based on these data, secondary peptide libraries con- C-terminal segment of Cdc5p (data not shown). We refer
taining a fixed Ser-pThr core were used to further refine to this additional region as the Polo-cap (Pc). For both
the motifs and investigate the relative importance of Pro
Plk1 and Cdc5p, we found no significant difference in
in the pThr1 position (Supplemental Tables S1 and S2
the phosphopeptide binding affinities of fragments en-available at Cell website). These data reveal that all Plks
compassing the entire C-terminal regions or the proteo-investigated, including all conventional human Plk ho-
lytically defined PBDs, indicating that the first 40mologs, select a similar motif that can be most generally
amino acids between the kinase and the Pc play norepresented by the consensus sequence:
major role in peptide binding. Shorter fragments of both
[Pro/Phe]-[φ/Pro]-[φ/AlaCdc5p/GlnPlk2]- Plk1 and Cdc5p lacking the Pc, were insoluble in E. coli,
indicating a clear structural role for the Pc in both pro-[Thr/Gln/His/Met]-Ser-[pThr/pSer]-[Pro/X]
teins.
The X-ray structure of a recombinant form of the pro-φ represents hydrophobic amino acids.
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Figure 1. Mutation of the Plk1 PBD Consen-
sus Motif Defines Specificity Requirements
for Phosphopeptide Binding
(A) Conservative mutations at the pT-1 serine
abolish Plk1 PBD-peptide binding in solution.
Isothermal titration calorimetry was used to
determine binding affinities. N.D.B. indicates
no detectable binding for a Plk1 PBD (resi-
dues 326–603) concentration of at least 150
M. pT denotes phosphothreonine.
(B) Binding of GST-Plk1 PBD (residues 326–
603) to a filter array of peptide spots, com-
prising single point mutants of the Plk1 PBD
optimal phosphopeptide (right column). Bound
GST-Plk1 was detected by blotting with HRP-
conjugated anti-GST antibody.
teolytically defined Plk1 PBD (residues 367–603) in com- 1/2 from PB1 and 6/7 from PB2, together with an
array of interactions with the intercalating linker regions.plex with its “optimal” phosphopeptide was solved by
multiwavelength anomalous diffraction, and refined at
1.9 A˚ resolution (Table 1). The structure (Figure 2B) Unusual PBD-Phosphopeptide Interactions
Are Crucial for Specificityshows that the PBD contains two 6 motifs that com-
prise the two Polo-box regions (PB1 and 2) identified The phosphopeptide binds in an extended conformation
to one end of a shallow cleft formed between the twoby sequence profiling. In spite of the fact that the amino
acid sequences of the two Polo boxes within any one Polo boxes (Figure 2). In all,1000 A˚2 of solvent accessi-
ble surface are buried by binding of the seven phospho-Plk exhibit only 20%–25% sequence identity, the
structures of the two motifs are quite similar (rms devia- peptide residues visible in our electron density maps.
Binding involves part of the only highly conserved sur-tion of 77 C atoms of 1.6 A˚; Figure 2B). The two Polo
boxes pack together to form a 12-stranded  sandwich face on the PBD (Figures 3A and 3B) explaining the
similar motifs selected by different PBDs. The bindingflanked by three -helical segments (Figure 2C). Al-
though motifs resembling the Polo-box structure are site also coincides with the only significant region of
positive electrostatic potential (Figure 3C). The phos-represented in the Protein Databank, the overall domain
fold is not. The Pc consists of an -helical segment A, phopeptide interacts predominantly with 1 from PB1,
the N-terminal end of L2 and 8/9 from PB2. Hydrogen-loop and short 310 helix that connects to the first  strand
of Polo-box 1 (1) through a short linker region (L1). The bonding interactions formed with the peptide side- and
main-chain atoms alternate to some degree betweenPc wraps around Polo-box 2 tethering it to Polo-box 1.
A packs against C from PB2 in an antiparallel coiled- residues within the two Polo boxes, forming a zipper-
like structure at the edge of the PB1/PB2 interface (Fig-coil arrangement, while the 310 helix packs against the
shorter C’. The two Polo boxes are connected by a ure 3D).
PBD binding to the phosphate moiety involves a com-second30 residue linker sequence (L2) that is partially
conserved. L1 and L2 run in antiparallel directions be- bination of direct contacts with protein side-chains and
extensive indirect interactions through a well-definedtween the two Polo-box sheets. Thus, the hydrophobic
core is formed from direct interactions of highly con- lattice of water molecules, many of which are fully hydro-
gen-bonded (Figure 3E). In total, the phosphate groupserved nonpolar residues predominantly located on
Cell
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Figure 2. Structure of the Plk1 PBD/Phos-
phopeptide Complex
(A) Defining the boundaries of the PBD by
limited proteolysis. Domain architecture of
full-length Plk1 and stable fragments (left) are
shown together with the time-course of V8
protease digestion (right). Molecular weight
and amino acid boundaries of the limiting
domain were determined by mass spec-
troscopy.
(B) Superposition of the Polo-box 1 and Polo-
box 2 6 structures, colored as in (A).
(C) RIBBONS representation (Carson, 1991)
of the structure of the Plk1 PBD in complex
with a pThr-containing peptide shown as a
ball and stick representation in yellow. The
Polo boxes and Polo-cap region are colored
as in (A). The phosphopeptide binds at one
end of a pocket formed between the two
polo boxes.
participates in eight hydrogen-bonding interactions, ex- the bound phosphopeptide compared with phospho-
peptide complexes of 14-3-3 proteins and FHA domains,plaining the critical dependence on phosphorylation for
binding (Elia et al., 2003). The only residues that contact the two major classes of pSer/pThr binding proteins
(Durocher et al., 2000; Yaffe et al., 1997). In these struc-the phosphate group directly are His-538 and Lys-540
from PB2, whose side chains form a pincer-like arrange- tures, the pThr-1 side-chain is solvent exposed and little
selection is observed at this position. In contrast, thement that chelates the O1, O3, and Ophosphate oxygens.
The extraordinarily high selectivity for serine at the peptide orientation in the Plk1 complex is inverted such
that the Ser–1 side-chain is directed toward the Plk1pThr-1 position results from a different orientation of
Structure and Function of the Polo-Box Domain
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Table 1. Crystallographic Analysis
Se
Dataset ( A˚) Native (0.98) (0.97838) Se (0.97887) Se (0.95)
Data Collection
14.1-SRS 14.2-SRS
d (A˚) 20.0–1.9 20.0–3.5 20.0–3.5 20.0–3.5
Completeness (%) 97.7 99.9 99.0 99.2
Redundancya 3.6 3.7c 1.9c 1.9c
Rsym (%)b 5.3 5.4c 5.2c 4.9c
Phasing analysis
Resolution bin (A˚) 20–11.2 11.2–7.5 7.5–6.0 6.0–5.2 5.2–4.6 4.6–4.2 4.2–3.9 3.9–3.6
FOM 0.79 0.83 0.79 0.70 0.59 0.53 0.48 0.44
Mean FOM 0.60
Refinement
Rcryst (%)d Rfree (%)e rmsbond (A˚) rmsangle (deg.)
23.0 25.8 0.007 1.2
a Nobs/Nunique
b Rsym  j|	I
  Ij|/	I
 where Ij is the intensity of the jth reflection and 	I
 is the average intensity.
c Calculated with Bijvoets separated
d Rcryst  hkl |Fobs  Fcalc|/hkl Fobs
e Rfree  as for Rcryst but calculated on 5% of the data excluded from the refinement calculation.
surface (Figure 3B). In this orientation, it engages in two entropic penalty for making this favorable backbone
contact. This contrasts with structures of pSer-Pro andhydrogen bonding interactions with Trp-414 main-chain
atoms, and one with the Leu-491 main-chain carbonyl pThr-Pro peptide complexes with the Pin1 WW and the
Cdc4 WD40 domains, respectively, in which the Pro1via a water molecule (Figure 3D). Significantly, the Ser–1
C atom makes favorable van der Waals interactions side chain inserts into a hydrophobic pocket and makes
coplanar interactions with a buried tryptophan (Orlickywith C1 from the Trp-414 indole side-chain. This ex-
plains why even a conservative replacement with Thr et al., 2003; Verdecia et al., 2000).
abrogates peptide binding (Figure 1A), presumably due
to a steric clash of the additional -methyl group with Plk1 and Sak Polo Boxes Are Structurally
Distinct—One Motif, Two FoldsTrp-414. In addition, the absolute conservation of Trp-
414 predicts that all family members should exhibit the The human Plk family encompasses the canonical ki-
nases (Plks 1–3) and Sak, which contains a highly homol-same serine preference, and this is, indeed, the case.
The critical role of Trp-414 in ligand binding revealed ogous Ser/Thr kinase domain but only a single divergent
Polo box. Recent structural data has shown that theby our crystal structure (Figure 3D) explains the observa-
tion that a W414F mutation eliminates both centrosomal isolated Polo box from murine Sak forms an intermolec-
ular dimer, leading to the suggestion that tandem Pololocalization of Plk1 and its ability to complement the
cdc5-1 ts (Lee and Erickson, 1997). Both of these effects boxes in Plk1-related Plks may form a related, intramo-
lecular “dimeric” architecture (Leung et al., 2002). Ourare likely to be at least partly attributable to disruption
of critical Ser-1 interactions with the PBD. In agreement structure shows that this notion is broadly correct. In
each case, the Polo-box repeat comprises a six-with this, a mutant PBD containing the W414F substitu-
tion is severely compromised in phosphopeptide bind- stranded  sheet and -helix, that associates with a
second Polo-repeat via intra- or intermolecular interac-ing, with an affinity of 
100 M as determined by ITC.
Loss of binding does not result from gross structural tions in Plk1 and Sak respectively, to form  sandwich
domain structures. However, closer examination revealsperturbation of the Polo-box fold, since the mutant and
wild-type PBDs show similar CD spectra (data not profound differences between the organization of the
two structures (Figure 4). Most strikingly, the associationshown).
Consistent with the library selection, the protein-pep- of the two Polo boxes differs completely such that resi-
dues forming the interface between Polo repeats in thetide interface is dominated by interactions of the PBD
with the pThr and Ser-1 (Figures 3C and 3D). Although Sak homodimer are located largely on the exterior of
the Plk1  sandwich, where they partially form the inter-we observed modest selection for Pro at the pThr1
position, the structure shows limited contribution to the face with the flanking -helical segments. The grossly
different architectures argue against conservation ofbinding interface, and multiple substitutions at this posi-
tion are tolerated for peptide binding (Supplemental Ta- phosphoprotein binding function since residues most
intimately involved in phosphopeptide binding by Plk1bles S1 and S2 available at Cell website; Figure 1B). In
the PBD structure, the trans-proline introduces a kink (e.g., His-538/Lys-540, Trp-414) are not conserved in
Sak. Furthermore, the electrostatic potential surface ofafter the Ser-pThr directing the peptide backbone back
toward the binding surface, allowing the pThr2 main the Sak Polo-box dimer shows no significant regions of
positive charge (data not shown), a property otherwisechain amino group to contact the PBD. Thus, the 1
Pro likely increases binding affinity by diminishing the common to phosphodependent binding proteins. Ex-
Cell
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Figure 3. Details of the Plk1 PBD/Phosphopeptide Interaction
(A) Structure-based sequence alignment of the Polo-box domain family. Residues with 100% conservation are shaded purple while highly
conserved residues are shaded cyan.
(B) The most highly conserved residues within the Plk1 PBD are located exclusively on the peptide binding face of the PBD. The coloring
scheme is as in (A).
(C) Electrostatic potential of the PBD phosphopeptide pocket, calculated using GRASP (Nicholls et al., 1991), with the phosphopeptide
superimposed in stick representation (oxygen atoms, red; nitrogen atoms, blue). Negative potential of the PBD surface is colored red and
positive potential blue.
(D) Schematic representation of the interactions between the phosphopeptide (blue) and the Plk1 PBD. Hydrogen bonds, van der Waals
interactions, and water molecules are denoted by dotted lines, purple crescents, and green circles, respectively.
(E) Schematic representation of direct and indirect hydrogen bonds (dotted lines) between the phosphate and the Plk1 PBD. Hydrogen bond
lengths are given in angstroms.
periments to determine whether the Sak Polo-box dimer 95%, though a small amount of phosphospecific bind-
ing was still observed. Mutation of both His-538 andis able to bind to phosphopeptides are underway.
Lys-540 eliminated phosphopeptide binding completely
as shown using both a bead-immobilized pThr-Pro ori-Mutation of the His-Lys Pincer Abolishes
ented library (Figure 5A) and by ITC (Figure 5B).Phosphopeptide Binding In Vitro, Cdc25
During mitotic entry, Cdc2/Cyclin B and Plk1 cooper-Binding In Vivo, and Centrosomal
ate to activate the dual specificity phosphatase Cdc25Localization of the Plk1 PBD
through extensive phosphorylation of its N terminus asTo verify that the key pThr-interacting residues identified
part of an amplification loop for Cdc2/Cyclin B activationin the X-ray crystal structure are responsible for mediat-
(Abrieu et al., 1998; Kumagai and Dunphy, 1992). Mitoti-ing phosphodependent interactions in vitro and in vivo,
cally phosphorylated Cdc25C exhibits a large mobilitywe mutated His-538 and Lys-540 of the pThr pincer
shift on SDS-PAGE (Kumagai and Dunphy, 1992) (brack-motif (Figure 5A). Mutation of His-538 to Ala reduced
ets labeled “P” in Figures 5C–5E), while Cdc25C in non-binding of in vitro translated Plk1 PBD to a bead-immo-
cycling cells or cells arrested in G1/S with aphidicolinbilized pThr-Pro oriented library by 50%. Mutation of
exhibit two lower mobility forms (brackets labeled “U”Lys-540 to Met, as a conservative structural replace-
ment for a partially buried lysine, reduced binding by in Figures 5C–5E). Cdc25C is phosphorylated on at least
Structure and Function of the Polo-Box Domain
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Figure 4. Topologies of the Polo Boxes from
Plk1 and Sak
(A) Comparison of the  sandwich folds of
the Plk1 PBD and the Sak Polo-box dimer.
Tertiary structures are shown on the top to-
gether with secondary structure topology (tri-
angles,  strands; rectangles,  helices) on
the bottom. PB1 of Plk1 is colored red while
the two Polo boxes of the Sak homodimer
are shown in red and blue, respectively. The
6 topology of the Plk1 Polo box is replaced
by a circularly permuted 5 topology in
Sak. Consequently, Plk1 1 has no equivalent
in the Sak Polo-box sequence and instead
overlaps structurally with Sak 6. In addition,
the Sak  sheet is completed by a “segment-
swap” of 4 and 5 between monomers.
(B) Sequence alignment of the Polo boxes
from Plk1 and Sak.  sheet and -helix nota-
tion follows PB1; the corresponding elements
for PB2 are 7 through 12 and C. A con-
served salt-bridging interaction, initially ob-
served in the Sak structural analysis (Leung
et al., 2002), is shown by the bracket with
the basic and acidic residues highlighted in
green. Conserved nonpolar residues are
highlighted in blue and residues conserved
between Sak and at least one of the Plk1
PBDs are boxed.
five Ser/Thr-Pro sites by Cdc2/Cyclin-B in vitro (Izumi cer in full-length Plk1 completely disrupted the in vivo
interaction between Plk1 and Cdc25C demonstratingand Maller, 1993; Strausfeld et al., 1994). One of these
sites, Thr-130, occurs within a near-optimal PBD binding that the interaction of the full-length molecules in G2/
M-arrested cells is mediated primarily through the PBD.motif, Leu-Leu-Cys-Ser-pThr-Pro-Asn. We previously
observed that a GST-fusion of the isolated PBD could This result is important since it directly demonstrates a
requirement for PBD phosphopeptide binding in sub-pull down wild-type Cdc25C, but not a T130A or S129V
Cdc25C mutant, from mitotically arrested HeLa cell ly- strate targeting in the context of the full-length Plk1
molecule. We did observe a small amount of binding ofsates. These data strongly suggested that Cdk priming
of Thr-130 generates a binding site for the Plk1 PBD the nonmitotically phosphorylated form of Cdc25C to
both the isolated PBD and full-length Plk1 (Figures 5Cto facilitate subsequent activation of Cdc25C by Plk1-
mediated phosphorylation (Elia et al., 2003). As shown and 5D), consistent with the fact that Cdc25C can serve
as a Plk1 substrate even in the absence of Cdk phos-in Figure 5C, expression of His-Xpress-tagged wild-type
Plk1 PBD in vivo results in a strong interaction primarily phorylation (Kumagai and Dunphy, 1992), albeit presum-
ably less efficiently.with the mitotically phosphorylated form of endogenous
Cdc25C in nocodazole-arrested HeLa cells. However, Finally, we observed that mutation of the His-538/
Lys-540 pincer eliminates targeting of the Plk1 PBD toexpression of the His-538/Lys-540 pincer mutants elimi-
nates Cdc25C binding as also observed in cells trans- centrosomes in permeabilized prophase-arrested cells
(Figure 5F). This finding suggests that the localizationfected with a PBD construct lacking the second Polo
box (residues 326–506). of Plk1 to centrosomes observed in vivo (Jang et al.,
2002; Lee et al., 1998) results from direct interactionsTo investigate whether the PBD plays a similar sub-
strate-targeting role in full-length Plk1, HeLa cells were between the PBD and phosphorylated centrosomal
components. In summary, these data show conclusivelytransfected with myc-tagged wild-type or mutant full-
length Plk1, and interactions between Plk1 and endoge- that the structurally defined His-538/Lys-540 pincer
mechanism that is responsible for mediating phospho-nous Cdc25C examined in nocodazole-arrested cells by
immunoprecipitation (Figure 5D and Supplemental Data peptide binding in vitro, plays a similarly critical role in
substrate targeting in vivo.available at Cell website). We observed a strong in vivo
interaction between the mitotically upshifted form of
endogenous Cdc25C with full-length Plk1 in arrested Phosphodependent Substrate Recognition
Is Necessary for the Disruption of Mitoticcells that, surprisingly, was not increased when a kinase-
dead Plk1 mutant (K82R) or a double mutant incorporat- Progression by the Isolated Plk1 PBD
Since the PBD is necessary for targeting Plk1 to primeding a T210D mutation in the T-loop to further expose
the substrate binding cleft were employed as substrate substrates, its overexpression might be expected to act
in a dominant-negative fashion to inhibit correct local-traps. Conversely, mutation of the His-538/Lys-540 pin-
Cell
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Figure 5. Mutation of the H538/K540 Pincer Sequence within the Plk1 PBD Abolishes Phosphopeptide Binding In Vitro and Cdc25 Binding
In Vivo
(A) Wild-type and mutant Plk1 PBD (residues 326–603) were translated in vitro in the presence of 35S-methionine and examined for binding
to an immobilized pThr-Pro-oriented library (pTP) and its unphosphorylated counterpart (TP).
(B) H538A/K540M mutation of the Plk1 PBD abolishes binding to its optimal phosphopeptide as measured by isothermal titration calorimetry.
(C) Mutation of the H538/K540 pincer disrupts interaction of the isolated Plk1 PBD with Cdc25 in vivo. HeLa cells were transfected with wild-
type and mutant versions of a His-Xpress-tagged Plk1 PBD construct (residues 326–603) or with a control Plk1PBD construct lacking the
second Polo box (residues 326–506). Cells were arrested in G2/M with nocodazole, the Plk PBD pulled down with NTA beads, and bound
endogenous proteins analyzed by SDS-PAGE. Immunoblots revealed preferential association of the PBD with the mitotically hyperphosphory-
lated form (P) of Cdc25C compared with hypophosphorylated form (U).
(D) Mutation of the H538/K540 pincer in the Plk1 PBD disrupts interaction of full-length Plk1 with Cdc25 in vivo. HeLa cells were transfected
with wild-type and mutant versions of full-length myc-tagged Plk1 and arrested in G2/M with nocodazole. Plk-myc was immunoprecipitated
with anti-myc-conjugated beads and Cdc25 binding to Plk1 analyzed as in (C).
(E) Hyper- and hypophosphorylated forms of Cdc25C. Lysates used in (C) and (D), along with a control lysate arrested in G1/S with aphidocolin,
were immunoblotted for Cdc25C.
(F) Centrosomal localization of the Plk1 PBD in HeLa Cells-U2OS cells were arrested in G2/M with nocodazole and then incubated with wild-
type or mutant GST-Plk1 PBD. Overlap of the GST and -tubulin signals is shown in the merged panel.
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1997; Mundt et al., 1997) while the isolated Plk1 C termi-
nus interacts with and inhibits the activity of the isolated
kinase domain in trans (Jang et al., 2002). Here, we show
that the kinase domain appears to inhibit phosphopep-
tide binding by the PBD. While the isolated Plk1 PBD
binds strongly and specifically to pSer/pThr-containing
peptides (Figure 5A), phosphopeptide binding by the
PBD within full-length Plk1 is reduced at least 10-fold
and is considerably less phosphodependent (Figure 7A,
wt lanes). However, the limited phosphospecific binding
component of full-length Plk1 is clearly mediated by the
PBD (Figure 7A, compare wt pTP and TP lanes with
H538A/K540M pTP and TP lanes). This suggests that a
mutually inhibitory interaction exists between the Plk1
PBD and the kinase domain in full-length Plk1. We won-
dered whether binding of the PBD to phosphopeptides
was sufficient to relieve this intramolecular interaction
and stimulate kinase activity. As shown in Figure 7B,
addition of the optimal PBD phosphopeptide increased
recombinant Plk1 kinase activity by a factor of 2.6, while
addition of the nonphosphorylated peptide had no ef-
fect. This result is comparable to the 2.5-fold stimula-
tion of full-length Src-family kinase activity that is ob-
served when incubated with their optimal SH2 binding
phosphotyrosine peptides (Liu et al., 1993; Moarefi et
al., 1997). Thus, our results for Plk1 suggest that binding
Figure 6. Mutation of the H538/K540 Pincer Prevents G2/M Arrest of the PBD to primed phosphorylation sites not only
and Aneuploidy Resulting from Overexpression of the Plk1 PBD in serves to target the kinase domain to substrates but
HeLa Cells also simultaneously activates the kinase domain for sub-
HeLa cells were transfected with wild-type and mutant GFP-tagged strate phosphorylation by relieving an inhibitory intra-
Plk1. Cells were harvested, stained with Hoechst 33342, and ana- molecular interaction (Figure 7D). The interaction be-
lyzed by FACS to determine DNA content in the total cell populations
tween the kinase domain and the PBD does not appear(left images). Similar analysis of the transfected cell population only
to involve the phosphopeptide binding site, since thewas performed by gating only on the GFP expressing cells (right
isolated kinase domain binds to both wild-type andimages). Percentages are averages from three independent experi-
ments. H538A/K540M mutant PBDs in trans (Figure 7C).
Discussion
ization of endogenous Plk1 and, thus, disrupt Plk1 func-
tion. Indeed, overexpression of the C terminus of Plk1 Structural Definition of the Polo-Box Domain:
has been shown to cause mitotic arrest and induce A Specialized Phosphoprotein
Recognition Moduleformation of randomly oriented, disorganized spindles
Previous reports have described the presence of 1–3(Jang et al., 2002; Seong et al., 2002). In agreement with
Polo boxes within the C-terminal regions of Polo-likeprevious studies, we found that overexpression of a
kinases (Glover et al., 1998; Nigg, 1998; Seong et al.,GFP-fusion of the Plk1 PBD in HeLa cells caused a
2002). Our X-ray structure now shows that the PBD con-dramatic increase in the population of cells in G2/M
sists of two structurally homologous regions corre-(60% for PBD-GFP versus 17% for GFP-expressing
sponding to two conserved Polo-box sequences. Phos-cells) (Figure 6). Importantly, this accumulation of mitotic
phopeptide binding occurs at the interface of the twocells was abolished by mutation of His-538 and Lys-540
Polo boxes, rationalizing both the observed 1:1 stoichi-(23% in G2/M). In addition, expression of the wild-type
ometry of PBD/ligand binding (Figure 5B) and the re-PBD-GFP construct induced aneuploidy in HeLa cells,
quirement for both Polo boxes for Plk1 localization inevident as a peak of cells with DNA content 
4N, in
vivo (Seong et al., 2002). Polo-box domains now joinagreement with anti-Plk1 antibody microinjection stud-
an expanding family of pSer/pThr binding domains thaties (Lane and Nigg, 1996). However, this effect was com-
includes 14-3-3 proteins, WW, FHA, WD40, and Smadpletely lost when the His/Lys pincer mutant was em-
MH2 domains (Yaffe and Smerdon, 2001). In contrastployed. The dominant-negative effects strongly suggest
to other more ubiquitous phosphodependent bindingthat phosphopeptide binding by the PBD in full-length
modules, PBDs occur only in Polo-like kinases wherePlk1 normally plays a role in both proper mitotic progres-
they localize Plks to specific subcellular organelles andsion and in the establishment of a functional bipolar
mitotic structures (Jang et al., 2002; Lee et al., 1998,spindle to ensure equal chromosome segregation.
1999).
Phosphopeptide Binding to the PBD Stimulates Common Phosphopeptide Motif Selection
Plk1 Kinase Activity by the PBD Family
Deletion of the C terminus of Plk1 has been observed In higher eukaryotes, different Plk family members func-
tion at different points in the cell cycle or play antagonis-to increase the kinase activity3-fold (Lee and Erikson,
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Figure 7. Intramolecular Inhibition of the Plk1
Kinase Domain by the PBD Is Relieved by
Ligand Binding.
(A) Phosphopeptide binding by full-length
Plk1 is reduced relative to that for the isolated
Plk1 PBD. Approximately 10% of input full-
length Plk1 (residues 1–603) interacted with
an immobilized pThr-Pro oriented library with
slight preference over the unphosphorylated
library analog in multiple experiments. The
phosphodependent binding component arose
from the PBD, as it was eliminated by muta-
tion of the His538/K540M pincer. In contrast,
phosphopeptide binding by the isolated PBD
(Figure 5A) was 10-fold greater and consider-
ably more phosphodependent.
(B) The optimal PBD phosphopeptide stimu-
lates full-length Plk1 kinase activity. GST-
Plk1 (prepared in SF9 cells) was preincubated
without peptide (closed circles), with 250 M
of the optimal PBD phosphopeptide (open
squares) or with 250 M of the nonphosphor-
ylated optimal peptide counterpart (closed
squares) for 5 min at room temperature prior
to initiating the kinase reaction by addition
of ATP. [32P]-incorporation into casein was
determined by SDS-PAGE electrophoresis,
autoradiography, and densitometry.
(C) The Plk1 kinase domain binds the PBD
at a site distinct from the phosphopeptide
binding pocket. The kinase domain was
translated in vitro in the presence of 35S-
methionine and incubated with beads con-
taining wild-type or mutant GST-PBD, or GST
alone (bottom image). Bound proteins were
analyzed by SDS-PAGE/autoradiography
(upper image).
(D) A model for Plk1 regulation by the PBD.
PB1 and PB2 are shaded orange, kinase do-
main cyan, phosphopeptide purple with
phosphate in red. Inhibitory interactions be-
tween the PBD and the kinase domain in the
basal state (left) are relieved by phosphopep-
tide binding (right).
tic roles in response to DNA damage. Given the similarity for Cdks and other proline-directed kinases in priming
substrates for Plk1 targeting. Several lines of evidencein the selected motifs for these three proteins, how do
individual Plks achieve substrate specificity? Potential support this model. For example, maximal Plk1-induced
activation and nuclear translocation of Cdc25 has beenmechanisms include different substrate selectivities by
their kinase domains, spatially and/or temporally re- shown to require cyclin B coexpression (Toyoshima-
Morimoto et al., 2002). Furthermore, full reconstitutionstricted activation of Plks by upstream kinases, or the
well documented cell-cycle regulation of Plk1 and 2 of purified APC activity requires prior synergistic phos-
phorylation of the APC by both Cdc2 and Plk1 (Golanexpression (Golsteyn et al., 1994; Lee et al., 1995; Ma
et al., 2003). et al., 2002). Nevertheless, a tolerance for residues other
than proline demonstrates that other mitotic kinasesIn addition to pThr-1 selectivity for serine, all PBDs
that we have examined exhibit some specificity for pro- may also serve as priming agents. In this regard, the
NIMA-related kinase Fin1 has been recently shown toline at the pThr1 position, emphasizing a central role
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increase Plo1 affinity for spindle pole bodies in S. pombe by direct interactions, usually with conserved arginine
side-chains. The importance of the Plk1 His/Lys pincer(Grallert and Hagan, 2002). Identification of substrates
is exemplified by our observations that mutation abro-for Plk family members, as well as the kinases involved
gates phosphopeptide binding in vitro, targeting of Plk1in substrate priming will be crucial in clarifying many of
to Cdc25C in vivo, and centrosomal localization, as wellthese issues.
as disrupting the ability of the isolated PBD to induce
G2/M arrest and aberrant spindle function. Recently,A Model for Phospholigand-Induced
downregulation of human Plk1 has been shown to inhibitPlk Activation
proliferation of cultured tumor cells (Elez et al., 2000; LiuTwo alternative models for intramolecular regulation of
and Erikson, 2003), indicating that Plks are potentiallykinase activity by a phosphopeptide binding domain
important targets for therapeutic intervention. Theare exemplified by Src-family kinases and SHP-family
unique pattern of interactions with the Ser-pThr dipep-tyrosine phosphatases. In the Src model, the phospho-
tide suggest that this motif may now be employed aspeptide binding cleft of the SH2 domain engages an
a template for the design of antiproliferative inhibitorsinternal phosphotyrosine motif at the C terminus of the
specifically directed against Polo-box domains.molecule to hold the kinase domain in an inactive confor-
mation (Sicheri et al., 1997; Xu et al., 1997). Plk1 does
Experimental Procedures
not appear to operate through this mechanism since it
does not possess an internal optimal PBD binding site. Cloning and Expression of PBD Proteins
Moreover, interaction of the PBD with the Plk1 kinase C-terminal fragments of human Plk1 (residues 326–603), human Plk2
(residues 355–685), human Plk3 (residues 335–646), Xenopus Plx1domain is not dependent on kinase domain phosphory-
(residues 317–598), and Saccharomyces cerevisiae Cdc5p (residueslation (Jang et al., 2002) and mutation of Thr-210 to Asp
357–705) were amplified from IMAGE cDNA clones or S. cerevisiaeas a mimic of activation loop phosphorylation, actually
chromosomal DNA by PCR and ligated into suitably digested
abolishes PBD binding (Jang et al., 2002). Since the His- pGEX4T-3 or pGEX-6P1 (Pharmacia). Point mutations were intro-
Lys pincer mutations that disrupt phosphodependent duced using the QuikChange mutagenesis kit (Stratagene). Proteins
were expressed in E. coli BL21(DE3) cells and purified by glutathi-interactions do not affect PBD-kinase interactions (Fig-
one-affinity chromatography. For measurements of peptide bindingure 7C), it would seem that inhibition occurs through
affinity and domain-mapping experiments, proteins were cleavedphosphoindependent binding by the PBD.
from GST with either thrombin or viral protease 3C (Pharmacia-In the SHP2 model, binding of the N-terminal SH2 LKB) and further purified by anion exchange chromatography or
domain to the phosphatase domain partially occludes gel filtration.
the catalytic cleft and deforms the SH2 domain’s binding
Domain Mapping and Protein Purificationpocket, reducing its phospholigand affinity (Hof et al.,
Limited proteolysis of Plk1 (residues 326–603) and Cdc5p were per-1998). This effect resembles the reduced phosphopep-
formed using trypsin or endoproteinase Glu-C (Promega). N- andtide binding that we observe for the PBD in the context
C-terminal limits were determined by Edman sequencing and elec-
of full-length Plk1 (Figure 7A). In the case of SHP2, high trospray mass spectrometry. DNA sequences encoding the proteo-
local concentrations of phosphotyrosine ligands are lytically defined domains were amplified by PCR and cloned into
able to bind to the N-terminal SH2 domain, inducing a pGEX-6P1 (Cdc5p) or a version modified to allow ligation-indepen-
dent cloning (S.J.S., unpublished data). Recombinant PBDs wereconformational rearrangement of the binding cleft. This
then expressed and purified as above.is transmitted to its phosphatase-interacting surface
and releases the catalytically competent phosphatase
Crystallization and Structure Determination
domain. We believe Plks may be regulated by a related For crystallization, the phosphopeptide MAGPMQSpTPLNGAYKK
mechanism (Figure 7D). Examination of the crystallo- was mixed with the Plk1 PBD fragment in a 1.5:1 stoichiometric
excess and concentrated to 0.2 mM in a buffer containing 20 mMgraphic temperature factors of the Plk1 PBD implies
Tris·HCl [pH 8.0]/500 mM NaCl, 1 mM EDTA, and 3 mM DTT. Crystalsa dynamic association of the two Polo boxes that is,
were grown by microbatch methods at 18C and belong to mono-presumably, more pronounced in the absence of the
clinic space-group P21 (a  62.4 A˚, b  79.5 A˚, c  62.0 A˚,  phosphopeptide ligand. Phosphopeptide binding may 93.3) with two complexes per asymmetric unit. Native data were
therefore act as a structural switch, stabilizing a PBD collected on Station 14.1 at the SRS, Daresbury (United Kingdom)
conformation that is inappropriate for association with using cryopreserved crystals at a temperature of 100K. All data
were reduced using the HKL suite of processing software (Otwinow-the kinase domain. Subsequent Thr-210 phosphoryla-
ski and Minor, 1997). Phase information was derived from a threetion by upstream kinases would then maintain the active
wavelength MAD experiment, using a single, plate-like crystal ofstate by preventing rebinding of the PBD to the kinase.
Se-methionine substituted PBD in complex with the phosphopep-
Proof or otherwise of this mechanism will require further tide. Data for each wavelength were collected to 3.5 A˚ spacing on
structural and biochemical analyses of full-length Plks Station 14.2 at the SRS, Daresbury. Ten Se sites (five per monomer)
were located, and the phases refined using SOLVE (Terwilliger andand their complexes.
Berendzen, 1999). Phases were extended to 2.5 A˚ against the
native data using real-space noncrystallographic symmetry averag-The Structural Basis of Phosphopeptide Binding
ing in RESOLVE (Terwilliger and Berendzen, 1999). These maps
The PBD binds to phosphorylated epitopes in a way that allowed a nearly complete model of the PBD, together with seven
is distinct from that observed previously in structures residues of the phosphopeptide to be built using “O” (Jones et al.,
1991). Subsequent refinement using native data to 1.9 A˚ was carriedof other protein-phosphopeptide complexes (Yaffe and
out using Refmac 5.0-ARP/wARP from the CCP4 suite. A summarySmerdon, 2001). Although stereospecific, solvent-medi-
of crystallographic statistics is shown in Table 1.ated binding has been described in other systems, such
extensive “solvent-bridged” interactions with the phos- Centrosomal Localization of the Plk1 PBD
phoryl group are not observed in other protein-phospho- U2OS cells were cultured in 8-well chamber slides and cycling cells
arrested in G2/M by treatment with nocodazole (50 ng/mL) for 14peptide complexes where the phospho moiety is held
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hr. After rinsing with PBS, cells were incubated with 4 M GST-Plk1 Glover, D.M., Hagan, I.M., and Tavares, A.A. (1998). Polo-like ki-
nases: a team that plays throughout mitosis. Genes Dev. 12, 3777–PBD (residues 326–603) and Streptolysin-O (1 U/ml) in permeabiliza-
tion buffer (25 mM HEPES [pH 7.9], 100 mM KCl, 3 mM NaCl, 200 3787.
mM sucrose, 20 mM NaF, and 1 mM NaOVO4) for 20 min at 37C. Golan, A., Yudkovsky, Y., and Hershko, A. (2002). The cyclin-ubiqui-
Cells were fixed in 3% paraformaldehyde/2% sucrose for 10 min at tin ligase activity of cyclosome/APC is jointly activated by protein
RT and extracted with a 0.5% Triton X-100 solution containing 20 kinases Cdk1-cyclin B and Plk. J. Biol. Chem. 277, 15552–15557.
mM Tris·HCl [pH 7.4], 50 mM NaCl, 300 mM sucrose, and 3 mM
Golsteyn, R.M., Schultz, S.J., Bartek, J., Ziemiecki, A., Ried, T., and
MgCl2 for 10 min at RT. Slides were stained with Alexa Fluor 488- Nigg, E.A. (1994). Cell cycle analysis and chromosomal localization
conjugated anti-GST (Molecular Probes) and monoclonal anti--
of human Plk1, a putative homologue of the mitotic kinases Dro-
tubulin (Sigma) antibodies at 4C overnight, then stained with a
sophila polo and Saccharomyces cerevisiae Cdc5. J. Cell Sci.
Texas Red-conjugated antimouse secondary antibody for 60 min at
107, 1509–1517.
RT and counterstained with 4 g/ml DAPI. Images were analyzed
Grallert, A., and Hagan, I.M. (2002). Schizosaccharomyces pombeusing NIH Image.
NIMA-related kinase, Fin1, regulates spindle formation and an affin-
ity of Polo for the SPB. EMBO J. 21, 3096–3107.Cell-Cycle Analysis
Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M.J., and Shoelson, S.E.HeLa cells were transfected with wild-type and mutant forms of
(1998). Crystal structure of the tyrosine phosphatase SHP-2. CellGFP-tagged Plk1 (residues 326–603) for 32 hr. Media containing
92, 441–450.floating cells was retained, and attached cells were released from
plates by trypsinization. The two cell populations were combined, Izumi, T., and Maller, J.L. (1993). Elimination of cdc2 phosphorylation
washed with PBS, and stained with Hoechst 33342 (10 g/mL) for sites in the cdc25 phosphatase blocks initiation of M-phase. Mol.
30 min at 37C in DMEM/10%FBS (1  106 cells/mL). Dead cells Biol. Cell 4, 1337–1350.
were stained by incubation with propridium iodide (5 g/mL) for 5 Jang, Y.J., Lin, C.Y., Ma, S., and Erikson, R.L. (2002). Functional
min at 4C. Fluorescent signals were quantitated on a FAC Star Plus studies on the role of the C-terminal domain of mammalian polo-
(Becton Dickinson) cell-sorting machine using Cell Quest software. like kinase. Proc. Natl. Acad. Sci. USA 99, 1984–1989.
Cell cycle analysis of total live cells (no propidium iodide staining)
Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard. (1991). Im-and live GFP-expressing cells (no propidium staining and GFP posi-
proved methods for binding protein models in electron density mapstive) was performed using Modfit 2.0.
and the location of errors in these models. Acta Crystallogr. A 47,
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